FDA Picks Nine Drugs for Fast-Track Reviews in New Program (1)

Oct. 17, 2025, 11:50 AM UTC

The US Food and Drug Administration on Thursday announced the first drug manufacturers that will receive expedited reviews as part of a new initiative to reward companies for acquiescing to the Trump administration’s stated policy priorities.

During a press conference, FDA Commissioner Marty Makary said that nine drugs have been chosen for priority vouchers.

The National Priority Voucher program offers recipients the option to accelerate decisions on medicines being reviewed by the agency. To qualify, the companies had to show they were returning drug manufacturing to the US, lowering drug prices for medications in their portfolios, addressing a public health ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.